Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models

Shigemi Fukami¹, Daisaku Tomioka¹, Yutaka Murakami¹, Toshiyuki Honda² and Shinji Hatakeyama³*

Abstract
Objective: A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models. The profiling data were generated during the drug discovery research prior to the first publication of TAE226 appeared in 2007 (Liu et al. in Mol Cancer Ther 6:1357–1367, 2007; Shi et al. in Mol Carcinog 46(6):488–496, 2007; Hald er et al. in Cancer Res 67(22):10976–10983, 2007).

Results: In a panel of 37 cancer cell lines, TAE226 showed a mean GI₅₀ value of 0.76 μmol/L. In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice. Oral administration of TAE226 induced tumor stasis at 30 mg/kg and tumor regression at 100 mg/kg in the subcutaneous tumor, and inhibited the orthotopic tumor growth in a dose-dependent manner. Similarly in the 4T1 model, TAE226 inhibited phosphorylation of Y397-FAK and S473-Akt in the cell culture in vitro and the tumor in mice. Oral administration of TAE226 inhibited the orthotopic tumor growth and metastasis to the lung in a dose-dependent manner. Thus, TAE226 represents a novel class of selective and small molecule kinase inhibitor with a potent in vivo activity.

Keywords: Focal adhesion kinase, Insulin-like growth factor-1 receptor, Cell proliferation, Anti-tumor

Introduction
Focal adhesion kinase (FAK) is a non-receptor cytoplasmic tyrosine kinase that regulates multiple cell functions [1]. A number of evidences suggest that FAK plays important roles in cancer cell proliferation and survival [2, 3]. Elevated mRNA and protein expression levels of FAK have been reported in breast, colon, prostate, ovarian, invasive thyroid tumors, and esophageal squamous cell carcinoma correlating with invasive potential [4–11]. On the other hand, overexpressing a kinase-dead FAK mutant (FRNK) showed prevention of experimental tumor metastasis to lung of v-src transformed cells [12]. Moreover, silencing of FAK by small interfering RNA decreases tumor growth [13]. These data suggest that FAK is overexpressed in preinvasive lesions and is sustained in invasive and metastatic tumors where overexpression of FAK confers a selective advantage to survive apoptotic stimuli during metastasis.

Insulin-like growth factor 1 receptor (IGF-1R) is a trans-membrane tyrosine kinase receptor expressed in a wide variety of cell types. High levels of IGF-1R, and/or its activating ligands IGF-1 and IGF-2 have been associated with various types of human cancer (e.g. multiple myeloma, breast, prostate, colon, lung, pancreas, Ewing’s sarcoma) and also found to correlate with increased invasiveness and metastatic potential [14–16]. IGF-1R has been shown to be necessary for anchorage-independent growth and survival, as well as for transformation by several oncogenes. Consistently, interference with its function by inhibiting its expression, by preventing ligand binding with an antibody, or by blocking its signaling
capacity with a truncated or kinase inactive form of the receptor has been shown to reduce tumor progression and/or metastasis formation in animal models [17, 18]. Furthermore, FAK is activated by IGF-1-mediated association of integrin β1 with IGF-1R in multiple myeloma cells grown in culture [19]. FAK and IGF-1R provide inputs into both Akt and MAPK pathway. Inhibition of both kinases should have a greater effect on important downstream effectors than inhibition of either enzyme alone.

Therefore, a dual inhibitor of both kinases may selectively block tumor growth, migration and survival of FAK- and IGF-1R-expressing tumor cells compared to proliferating and migrating normal cells. TAE226, a potent dual inhibitor of FAK/IGF-1R, has been described in literatures since the first publication of TAE226 appeared in 2007 [20–22] and its kinase selectivity has been also reported elsewhere [23, 24]. Here we report pharmacological profiles of TAE226 generated during the course of drug discovery research conducted until 2004.

Main text
Methods
Cellular proliferation assays
Sulforhodamine B assay was used for adhesive cell lines according to the procedure of National Cancer Institute [25]. Cell lines were cultured in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum and antibiotic–antimycotic solution at 37 °C with 5% CO₂. Dependent upon cell doubling time, between 5000 and 20,000 cells were inoculated into 96 well microtiter plates in a volume of 100 µL per well. Plating density of each cell lines used in this study was listed in Additional file 1: Table S1. The plates were incubated at 37 °C, 5% CO₂ for 24 h prior to the addition of TAE226. TAE226 was dissolved in DMSO at a concentration of 10 mM and stored in aliquots at −20 °C. Prior to use, an aliquot of frozen concentrate was thawed and additional half-log dilutions (1:3.16) for a total of eight drug concentrations were prepared in DMSO. At time of drug addition, each dilution was further diluted to twice the desired final concentration. After 24 h incubation, an aliquot of 100 µL of each drug dilution was added to the appropriate well in triplicate that already contains 100 µL of medium containing the cells. Time zero (Tz) control wells were fixed in situ by the gentle addition of 50 µL of 50% TCA to establish the cell population at time of drug addition.

The plates were then incubated for 48 h at 37 °C, 5% CO₂. Cells were fixed in situ with 50% TCA and incubated for 60 min at 4 °C. Plates were washed three times with distilled water after the supernatant was discarded and air dried. Then, 100 µL of 0.4% Sulforhodamine B (Cat No. 018-10012: Wako Pure Chemical Industries, Ltd., Tokyo, Japan) solution in 1% acetic acid was added to each well, the plates were incubated for 30 min at room temperature. Unbound dye was removed by washing three times with distilled water and the plates were air dried. The bound stain was solubilized with 10 mM Tris base and the values of OD₅₁₅ were measured by microtiter plate reader.

Percentages of net cell growth were calculated with the values of test growth in the presence of drug (Ti), growth control (C) and Tz according to the formula: \( [(T_i - T_z) ÷ (C - T_z)] × 100 \). Compound concentration required for 50% net growth inhibition (GI₅₀) values were determined by non-linear curve fit analysis using the OriginPro (OriginLab Corporation, Northampton, MA, USA).

AlamaeBlue (Dainippon Pharmaceutical Co., Ltd., Tokyo, Japan) assay was used for suspension cell lines according to manufacturer's protocol. In brief, one-tenth of AlamaeBlue was added into each well after 48 h incubation with the compound and the values of OD₅₇₀ minus OD₆₆₀ were measured by microtiter plate reader after 3 h incubation at 37 °C. Percentages of gross cell growth were calculated with the values of test growth in the presence of drug (Ti) and growth control (C) according to the formula: \((T_i ÷ C) × 100\).

Animal experiments
Animal experimental procedures in this study were in compliant with the regulations of Animal Welfare Committee in Novartis Institutes for BioMedical Research Tsukuba. The following mouse strains at the age of 5- to 6 weeks were purchased from Charles River (Yokohama, Japan): male BALB/c-nu/nu mice for MIA PaCa-2 subcutaneous inoculation; male C.B-17/lcrCrj-scid/scid mice for MIA PaCa-2 orthotopic inoculation; and female BALB/c mice for 4T1 orthotopic inoculation. Average body weight was 24 g with male BALB/c-nu/nu mice, and 18 g with male C.B-17/lcrCrj-scid/scid and female BALB/c mice. During inoculation, animals were anesthetized with isoflurane using a small animal anesthetizer. The mice bearing MIA PaCa-2 subcutaneous tumors and 4T1 orthotopic tumors with acceptable morphology, such as one round to oval shapes, excluding elongated thin rod-like shapes and split patterns, and size were randomized (7–8 mice per group). The mice bearing MIA PaCa-2 orthotopic tumors with acceptable luciferase activity detected by Xenogen system were randomized (8 mice per group). The mice were housed in a group of
4 to 5 per cage with access to water and food ad libitum in a normal light cycle room with specific pathogen free condition. At the end of the experiment, the mice were euthanized under terminal inhalation anesthesia with isoflurane followed by blood collection from abdominal vein.

**Immunoblotting analysis**

The tumor samples were pulverized in a CRYO-PRESS frozen cell crasher (#CP-100W, Microtec, Chiba, Japan). Samples were lysed by addition of 300 to 500 μL ice-cold T-PER Tissue Protein Extraction Reagent (#78510, Pierce, Rockford, IL, USA) containing protease inhibitors (#P2714, Sigma-Aldrich, St. Louis, MO, USA), and rotated at 4 °C for 30 min. Lysates were clarified by centrifugation at 15,000×g for 20 min at 4 °C. The antibodies used in this experiment are listed here: anti-phosphorylated ERK1/2, anti-ERK1/2, anti-phosphorylated Akt (pS473) and anti-Akt antibodies from Cell Signaling Technology (#9101, #9102, #9271 and #9272, respectively, Beverly, MA, USA); anti-phosphorylated FAK (pY397) antibody from Biosource International (#44-624, Camarillo, CA, USA); anti-FAK antibody from Upstate Biotechnology (#06-543, Lake Placid, NY, USA). Equal amounts of protein (tumor sample; 50 μg, cell lysates; 15 μg) were electrophoresed on 4–20% gradient SDS-PAGE gels (#301506, Dai-ichi pure chemicals, Tokyo, Japan) and transferred to an Immobilon-P PVDF membrane (#IPVH00010, Millipore, Bedford, MA, USA). Immunoblotting of transferred proteins was performed with appropriate antibodies (1:1000 dilutions) overnight at 4 °C. The membranes were washed in TBS-T (10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) and incubated with HRP conjugated donkey anti-rabbit IgG with 1:1000 dilution (#NA9340V, Amersham, Arlington Heights, IL, USA) at room temperature for 1 h. The membranes were washed extensively, and the proteins were visualized by enhanced chemiluminescence (#34095, SuperSignal West Femto Maximum Sensitivity Substrate, Pierce, Rockford, IL, USA). Signals were quantified by utilizing a LAS-1000plus image analyzer and ImageGauge software (Fuji Film, Tokyo, Japan).

**Compound treatment and statistical analyses**

TAE226 was formulated in Sandimmune–Neoral Placebo drink solution and administered once daily through oral gavage in a volume of 10 mL/kg. Tumor volumes were calculated according to the formula: length × width²/2. In efficacy experiments, the treatments were initiated when the mean tumor volumes reached approximately 150 mm³ for MIA PaCa-2 subcutaneous tumors and approximately 70 mm³ for 4T1 tumors. 4T1 cells were inoculated subcutaneously into the mammary fat pad of female BALB/c mice. In case of MIA PaCa-2 orthotopic tumors, a stable line expressing luciferase was created and mice bearing tumors with acceptable luciferase activity detected by Xenogen system were randomized and used in the experiment. Treatment was started at 24 days (=day 0) after MIA PaCa-2 cells were surgically implanted into pancreas of male CB17-SCID mice. Tumors were weighed after normal pancreas tissues were removed at day 24. Since tumor weights at day 0 cannot be measured, T/C values are calculated only with the weights at the end of treatment. Note that a little normal pancreas tissues were still remained, although it was removed as much as possible. Statistical analyses were performed by SYSTAT (SYSTAT Software Inc., Point Richmond, CA, USA). Differences were considered to be significant when the probability value was < 0.05.

**Results and discussion**

TAE226 was evaluated in a panel of 37 cancer cell lines comprising breast, prostate, lung, colon, stomach, pancreas, glioma, melanoma and myeloma to profile the in vitro anti-proliferative activity and showed a broad spectrum of activity in the panel with the mean GI₅₀ value of 0.76 μmol/L, ranging from 0.14 to 3.6 μM (Table 1). TAE226 was effective in P-glycoprotein expressing MCF-7/ADR-RES with a comparable potency in the parent line MCF-7, suggesting that TAE226 is not a substrate of P-glycoprotein. Potent anti-proliferative activity of TAE226 against wide range of cancer cell lines including multi-drug resistant cells indicated that TAE226 is effective against tumors that are resistant to conventional anti-cancer drugs.

Next, the effect of TAE226 on phosphorylation of FAK, Akt and ERK1/2 was evaluated in MIA PaCa-2 cells in vitro and tumors in vivo. Phosphorylation of FAK at Y397 and phosphorylation of Akt at S473 at all doses tested, but the effect on phosphorylation of ERK1/2 was not clear in vivo (Fig. 1b).

Anti-tumor activity of TAE226 was evaluated in the MIA PaCa-2 subcutaneous and orthotopic xenograft models. Oral administration of TAE226 efficiently inhibited MIA PaCa-2 tumor growth at all doses tested.
Table 1 Anti-proliferative activity of TAE226 against cancer cell lines

| Cell origin | Cell line name | GI50 (μM) | n |
|-------------|----------------|-----------|---|
| Breast      | MCF-7          | 1.2 ± 0.22| 7 |
|             | MCF-7/ADR-RES  | 1.1 ± 0.23| 4 |
|             | MDA-MB-231     | 0.56 ± 0.22| 3 |
|             | MDA-MB-435     | 1.6 ± 0.044| 3 |
|             | MDA-MB-453     | 1.5 ± 0.32| 3 |
|             | 4T1            | 0.16 ± 0.022| 5 |
|             | MTF7           | 1.4 ± 0.26| 3 |
| Prostate    | DU145          | 0.23 ± 0.025| 2 |
| Lung        | PC-3/M         | 0.83 ± 0.29| 4 |
|             | NCI-H23        | 0.29 (0.24, 0.35)| 2 |
|             | NCI-H460       | 0.40 ± 0.028| 4 |
|             | LLC            | 0.13 ± 0.0077| 4 |
| Colon       | COLO205        | 0.21 (0.11, 0.30)| 2 |
|             | HCT-15         | 0.71 ± 0.1 | 5 |
|             | HCT-116        | 0.42 ± 0.056| 3 |
|             | SW620          | 0.51 ± 0.024| 3 |
|             | WiDr           | 0.14 ± 0.030| 5 |
| Stomach     | KATOIII        | 0.54 ± 0.064| 3 |
| Pancreas    | BxPC-3         | 0.53 ± 0.11| 3 |
|             | Mia PaCa-2     | 0.26 ± 0.062| 4 |
|             | Panc-1         | 3.6 ± 0.93 | 3 |
|             | SUIT-2         | 0.18 ± 0.029| 3 |
| Glioma      | A172           | 1.6 (2.2, 1.1)| 2 |
|             | D8TRG-05MG     | 0.47 ± 0.054| 3 |
|             | LN-18          | 0.96 ± 0.12 | 3 |
|             | LN-229         | 0.56 ± 0.043| 3 |
|             | T98G           | 0.42 (0.21, 0.63)| 2 |
|             | U-87 MG        | 1.0 (1.1, 0.97)| 2 |
|             | U-118 MG       | 1.3 (0.69, 1.8)| 2 |
|             | U-373 MG       | 1.4 (0.72, 2.0)| 2 |
| Melanoma    | A375M          | 0.29 (0.15, 0.43)| 2 |
|             | C32            | 1.8 ± 0.31 | 3 |
|             | C8161          | 0.90 (0.68, 1.1)| 2 |
|             | SK-MEL-23      | 0.17 ± 0.0090| 3 |
|             | SK-MEL-93      | 0.25 ± 0.050| 4 |
|             | WM1158         | 0.33 ± 0.099| 3 |
| Myeloma     | RPMI8226       | 0.33 ± 0.060| 3 |

TAE226 concentrations causing 50% inhibition of net cell growth (GI50) are given. Results are expressed as mean ± SEM (except experiments with n = 2 where 2 individual values are included). Cell growth was assessed by sulforhodamine B staining for adhesive cell lines and by AlamarBlue for suspension cell lines. GI50 values were calculated after 48 h treatment with TAE226.

After 14 days treatment, T/C values were 50% at 10 mg/kg and 13% at 30 mg/kg, qd for 7×/week (Fig. 1c, Additional file 2: Table S2). At a dose of 100 mg/kg, qd for 5×/week, tumor regression (17%) was observed (Fig. 1c). A reference anti-cancer agent for pancreas carcinoma, gemcitabine at the maximum tolerated dose was moderately effective against Mia PaCa-2 model (T/C: 50%), which was similar to the report [26]. TAE226 also inhibited Mia PaCa-2 orthotopic tumor growth in pancreas dose-dependently (Fig. 1d). Body weight loss was not observed in TAE226-treated group in both experiments. Efficacy of TAE226 at 10 mg/kg in the subcutaneous tumor and at 30 mg/kg in the orthotopic tumor was comparable to that of gemcitabine at the maximum tolerated dose, and therefore TAE226 showed superior safety margin to gemcitabine.

Then, the effect of TAE226 on phosphorylation of FAK, Akt and Erk1/2 was evaluated 4T1 cells in vitro and tumors in vivo. Phosphorylation of FAK at Y397, Akt at S473 and ERK was observed in 4T1 cells (Fig. 2a) and 4T1 tumors (Fig. 2b). TAE226 inhibited phosphorylation of FAK at Y397, resulting in suppression of phosphorylation of Akt at S473 and ERK1/2 in 4T1 cells 1 h after treatment (Fig. 2a). In 4T1 tumors collected 3 h after administration of TAE226, TAE226 inhibited phosphorylation of FAK at Y397 and phosphorylation of Act at S473 at all doses tested, but the effect on phosphorylation of ERK1/2 was not clear in vivo (Fig. 2b). Degradation products of FAK, which were also detected by anti-N-terminal FAK antibody (data not shown), were observed in the 4T1 experiment (indicated by diamond arrow: pY397*).

4T1 is a highly malignant murine carcinoma cell line and spontaneously metastasizes to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ [5]. The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely resembles the situation in breast carcinoma patients. In the model, anti-tumor and anti-metastasis activities can be assessed at the same time. Oral administration of TAE226 inhibited 4T1 tumor growth and metastasis to the lung in a dose-dependent manner. Primary tumor growth was significantly inhibited by the dose of as low as 10 mg/kg. After 14 days treatment, T/C values were 67%, 50% and 18% at 10 mg/kg, 30 mg/kg, qd for 7×/week and 100 mg/kg, qd for 5×/week, respectively (Fig. 2c, Additional file 3: Table S3). Metastasis to lung was prevented with T/C values of 37% and 14% by the 30 mg/kg dose qd for the 30 mg/kg dose qd×7 and 100 mg/kg qd×5, respectively (Fig. 2d, Additional file 3: Table S3). The compound was well tolerated in mice as determined by measuring changes in body weight. A reference anti-cancer agent for breast carcinoma, doxorubicin, was moderately effective against 4T1 model (T/C: 50% primary tumor, 36% metastasis) at the maximum tolerated dose (Fig. 2c, d, Additional file 3: Table S3). Efficacy of TAE226 at 30 mg/kg was comparable to that
of doxorubicin at the maximum tolerated dose, and therefore TAE226 showed superior safety margin to doxorubicin.

As inhibition of tumor growth by TAE226 appears to correlate with inhibition of FAK and Akt as a surrogate of IGF-1R signaling pathway, TAE226 represents a novel class of selective and small molecule kinase inhibitor with potent in vivo activity.

**Limitations**

Further characterization of TAE226 will be required, for example, in pharmacokinetics and safety assessment to define safety margin as well as in patient-derived cells.
and tumors to stratify target patient population and tumor types. Some methods used in this study may be outdated since the profiling was performed in early 2000.

Additional files

Additional file 1: Table S1. Plating density of cell lines used in panel screening.
Additional file 2: Table S2. Effects of TAE226 on MIA PaCa-2 subcutaneous tumor growth and body weight change.

Additional file 3: Table S3. Effects of TAE226 on 4T1 primary tumor growth, body weight change and lung metastasis.

Abbreviations
BWC: body weight change; ERK: extracellular signal-regulated kinase; FAK: focal adhesion kinase; GI50: growth inhibition of 50%; IGF-1R: insulin-like growth factor 1 receptor; LWG: lung weight gain; T/C: tumor/control; TV: tumor volume.

Acknowledgements
We thank Novartis Institutes for BioMedical Research for their support.

Authors' contributions
SE, DT, YM, TH and SH contributed to planning the experiments. SE, DT, YM and SH conducted the experiments and analyses, and SH drafted the manuscript. All other authors edited and revised the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used in the current study are available from the corresponding author by request.

Ethics approval and consent to participate
Animal experimental procedures in this study were in compliant with the regulations of Animal Welfare Committee in Novartis Institutes for BioMedical Research Tsukuba.

Consent for publication
Not applicable.

Competing interests
All authors are or were employees of Novartis Pharma at the time of the work was carried out.

Author details
1 Novartis Institutes for BioMedical Research, Novartis Pharma KK, Tsukuba, Ibaraki, Japan. 2 Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA. 3 Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Received: 16 May 2019 Accepted: 13 June 2019 Published online: 18 June 2019

References
1. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71:435–78.
2. Parsons JT, Martin KH, Slack JK, et al. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000;19:5606–13.
3. Hecker TP, Gladson CL. Focal adhesion kinase in cancer. Front Biosci. 2003;8:705–14.
4. Werner TM, Liu ET, Craven RJ, et al. Expression of focal adhesion kinase gene and invasive cancer. Lancet. 1993;342:1024–5.
5. Owens LV, Xu L, Craven RJ, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995;55:2752–5.
6. Tremblay L, Hauck W, Aprikian AG, et al. Focal adhesion kinase (p125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer. 1996;68:164–71.
7. McCormack SJ, Brazinski SE, Moore JL Jr, et al. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene. 1997;15:265–74.
8. Kornberg LJ. Focal adhesion kinase expression in oral cancers. Head Neck. 1998;20:634–9.
9. Miyazaki T, Kato H, Nakajima M, et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 2003;89:140–5.
10. Gabarra-Nieko V, Schaller MD, Duntly JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003;22:359–74.
11. Lark AL, Livasy CA, Calbo B, et al. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res. 2003;9:215–22.
12. Hauck CR, Hisa DA, Puente XS, et al. FRNK blocks v-src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 2002;21:6289–302.
13. Tsutsumi K, Yamaura T, Nakajima M, et al. Silencing of focal adhesion kinase by tumor direct injection of small interfering RNA decreases in vivo tumor growth. Cancer Biol Ther. 2009;8:1292–9.
14. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor I and prostate cancer risk: a prospective study. Science. 1998;279:563–6.
15. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 1998;351:1393–6.
16. LeRoth D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–37.
17. Reiss K, D’Ambrosio C, Tu X, et al. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res. 1998;4:2647–55.
18. Liu X, Turbyville T, Fritz A, et al. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res. 1998;58:5432–8.
19. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 2003;303:58580–8.
20. Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007;6:1357–67.
21. Shi Q, Hjelmeland AB, Keit ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog. 2007;46(6):488–96.
22. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007;67:10976–83.
23. Kawahara E, Yamaura T, Ohmori O, et al. Discovery of a novel FAK inhibitor, NVP-TAE226, and its activities on in vivo and in vitro models. Eur J Cancer. 2006;42(Suppl):170.
24. Otani H, Yamamoto H, Takaoka M, et al. TAE226, a bis-anilino pyrimidine compound, inhibits the EGFR-mutant kinase including T790M mutant to show anti-tumor effect on EGFR-mutant non-small cell lung cancer cells. PLoS ONE. 2015;10:e0129838.
25. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82:1107–12.
26. Duxbury MS, Ito H, Benoit E, et al. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003;311:786–92.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.